Thirty years after the Center for Disease Control (CDC) reported the first US case of Acquired Immune Deficiency Syndrome (AIDS), the disease continues to stretch its shroud of death across the world. This, despite the billions of dollars that have been invested in the development of vaccines, spent on anti-retroviral therapies, and strewn about in condom distribution and sexual education schemes.

But there is a strange and disturbing trend now evident in the new cases of HIV/AIDS being reported, and it concerns women of reproductive age.

WASHINGTON, D.C., AUG. 25, 2010 (Zenit.org).- On Aug. 13, the U.S. Food and Drug Administration (FDA) announced the approval of a new "emergency contraceptive" called "Ella." Its competitor, Plan B, is said to "prevent pregnancy" up to 72 hours (3 days) after intercourse. Ella boasts of 120 hours (5 days) of post-coital effectiveness. The drug is produced by the Paris-based pharmaceutical company HRA Pharma and will be marketed by Watson Pharmaceuticals based out of Morristown, New Jersey. The FDA advisors voted unanimously to approve the drug.